EurActiv Logo
 
3 December 2009
Breaking News:

Extended Impact Assessment of a Draft EC Regulation on Medicinal Products for Paediatric Use 

Published: Monday 21 February 2005   

This impact assessment of the draft regulation on paediatric medicines was conducted by RAND Europe for the European Commission. 

The paper draws the conclusion that the EU's new regulation on medicinal products for paediatric use will cost money to industry, government and consumer but will improve the health of children and, on balance, the gains will outweigh the losses.

This document was put together by Wija J. Oortwijn, Edwin Horlings, Silvia Anton, Mirjam van het Loo and James P. Kahan, can be downloaded from the RAND websiteexternal .

IMPORTANT: 'Letters To The Editor' documents are commentaries by external contributors. EurActiv - as a neutral platform - does not state policy positions of its own. Any opinions in 'Letters to the Editor' documents are those of the author only.
Letters To The Editor
Concerns over mercury use in dental amalgam
Genon Jensen, Executive Director, Health and Environment Alliance
Advertising
 
Section Sponsors
Advertising